Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

NCT06892548 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06892548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06892548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 2, 2025
Completion date
May 31, 2032
Enrollment
594 (estimated)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung cancer